Earlier lung cancer diagnosis exposed major delays in curative radiotherapy access
In 2024, only 3.2% of English patients began curative radiotherapy within the 49-day target despite rapidly rising demand.
Latest
High-dose chemotherapy was linked to radiographic brain injury after proton therapy for medulloblastoma
Radiographic brain injury occurred in 16% of children, all asymptomatic; every affected patient had received high-dose chemotherapy.
Children’s Oncology Group guidelines standardize pediatric radiotherapy simulation across treatment sites and techniques
COG guidelines standardize pediatric radiotherapy simulation across treatment sites and techniques
Fifteen years of radiotherapy data were converted into an AI-ready resource
An open-source workflow structured 15 years of radiotherapy data, although reirradiation prediction showed only modest discrimination.
Dose-guided positioning optimized proton target coverage within three minutes
Automated dose-guided positioning matched anatomical alignment overall and improved primary target coverage by 1.0% when the clinical goal was initially missed.
Transformer dose engine achieved near-Monte Carlo accuracy for carbon ion therapy
The Transformer calculated carbon-ion pencil-beam doses in 14 milliseconds with 98.0% gamma agreement at stringent 1%/1 mm criteria.
Tetrandrine trial will test prevention of lung injury during esophageal chemoradiotherapy
A randomized phase II trial will test whether intravenous tetrandrine reduces grade 2 or higher lung injury from 25% to 10%.
FLASH altered early molecular responses without improving breast cell survival
Electron FLASH changed DNA-damage, transcriptomic, cytokine, and microtubule responses but did not alter clonogenic survival under normoxic conditions.
NanOx incompletely predicted laryngeal cancer cell survival across a helium Bragg peak
NanOx predictions differed from measured laryngeal cancer cell survival by 20–37% and overestimated the distal biological gradient.
Experts prioritized biomarker-guided radiotherapy–systemic therapy trials in head and neck cancer
International experts identified eight research priorities covering biomarker-guided chemoradiation, immunotherapy sequencing, and consolidation radiotherapy in metastatic head and neck cancer.
TFDP2-PDK3 metabolic signaling drove nasopharyngeal carcinoma radioresistance
TFDP2 activated PDK3, shifted nasopharyngeal carcinoma cells toward glycolysis, and reduced radiation response in cellular and xenograft models.
Concurrent olaparib increased severe dermatitis during radiotherapy for inflammatory breast cancer
Adding low-dose olaparib increased grade 3 dermatitis from 5.5% to 24.7% during postmastectomy radiotherapy for inflammatory breast cancer.
Tomotherapy improved lung sparing in whole-pleural irradiation for disseminated thymic tumors
Tomotherapy improved target coverage and reduced bilateral lung exposure compared with VMAT and fixed-field IMRT in 20 whole-pleural irradiation cases.
Early ventilation changes predicted end-of-treatment lung function after radiotherapy
Early-treatment ventilation direction persisted to treatment completion in most photon- and proton-treated patients, with the prediction model explaining 89% of variation.
Short-course total neoadjuvant therapy improved five-year survival in STELLAR
Five-year overall survival was 78.1% with short-course total neoadjuvant therapy versus 69.7% with long-course chemoradiotherapy.